Urate-Lowering Therapy After a Heart Attack: Allopurinol or Febuxostat in Stage 3b CKD
A single patient, three years past a myocardial infarction, needs urate-lowering therapy restarted after a gout flare. The disagreement isn't about whether he needs a xanthine oxidase inhibitor — it's about which one, once his cardiac history and his kidneys are weighed against each other rather than separately.
Ray T., a 62-year-old man, spent thirty years supervising a distribution warehouse before retiring last spring, and has filled the time since mostly in his backyard, coaxing a bed of dahlias through their second real season. He came in today limping slightly, the second metatarsophalangeal joint of his right foot swollen and warm — a gout flare, his third in two years, each one closer together than the last. He was on allopurinol 100mg once briefly after his first flare but stopped it himself within a few weeks, unconvinced it was doing anything at a dose that low, and nobody restarted or retitrated it afterward.
What makes today's decision harder than his last flare is what happened in between: an anterior myocardial infarction three years ago, treated with a drug-eluting stent, and a slow decline in kidney function since — his creatinine has drifted from 1.1 to 1.9 over that time, and today's basic panel puts his eGFR at 38, stage 3b chronic kidney disease attributed to a decade of hypertension layered on top of the infarct's own effect on renal perfusion. Both facts point at the same drug class from opposite directions. Febuxostat is cleared almost entirely by the liver, so stage 3b CKD changes nothing about its dosing — genuinely convenient in a patient whose kidneys are already a moving target. But the CARES trial randomized more than six thousand gout patients with established cardiovascular disease to febuxostat or allopurinol specifically to test long-term cardiovascular safety, and found a higher rate of cardiovascular death in the febuxostat arm even though the two drugs lowered urate equally well — a finding confined to patients who, like Ray, already had known cardiovascular disease at enrollment. He is not a hypothetical high-risk patient for that trial. He is exactly its population.
Choosing the xanthine oxidase inhibitor, three years after his stent
His creatinine has moved in one direction for three straight years, and I would rather start him on a drug whose dosing doesn't have to be re-solved every time his eGFR drops another few points. Febuxostat is cleared almost entirely hepatically — stage 3b CKD, even stage 4 if we get there, changes nothing about how it's dosed. Allopurinol at a renally-adjusted starting dose is manageable, but it adds one more variable to a kidney trajectory I'm already tracking closely.
I understand the appeal, but CARES randomized over six thousand gout patients who already had cardiovascular disease at enrollment — his exact profile, not an adjacent one — to febuxostat or allopurinol, and found more cardiovascular deaths in the febuxostat arm despite equal urate control. That's the reason the FDA boxed warning exists at all. His kidneys are a real problem to manage, but they are not the problem that trial was built to answer.
Renal convenience is a genuine point, but it's answering a different question than the one his cardiac history is actually asking. A drug that's easier to dose isn't the same thing as a drug that's safer for him specifically.
You're both right about your own data, and I don't think the renal argument actually favors febuxostat as strongly as it first sounds. The 2020 ACR guideline moved away from a fixed renal dose ceiling for allopurinol years ago specifically because start-low-titrate-to-target works across a wide range of kidney function, including his — it just requires checking urate and creatinine along the way, which we're already doing. His one prior trial at 100mg for three weeks was never titrated or monitored; it isn't evidence allopurinol doesn't work for him, only that it was never really tried.
He's also low-risk for HLA-B*5801 by ancestry, so the severe hypersensitivity concern that drives testing in some populations isn't a live issue here — worth naming since it's often the first objection raised against allopurinol.
Agreed: allopurinol restarted at a renally-cautious dose with colchicine prophylaxis, and a follow-up basic panel plus urate level in three weeks to guide the next titration step. All three voices signed off on the same plan once the cardiovascular data were weighed directly against the renal-convenience argument rather than considered separately.
Not fully closed: how far to push the allopurinol dose if his eGFR keeps falling before target urate is reached. The nephrologist wants a lower ceiling and more frequent labs if his renal function declines further during titration; the pharmacologist would keep titrating toward target urate regardless, arguing the guideline's own reasoning doesn't change with a few more points of eGFR. That question was deferred to whichever of them sees him at the next renal function check.